CancerDrs

Ovarian Cancer clinical trials in Alaska

9 actively recruiting ovarian cancer trials at 2 sites across Alaska.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Alaska:
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Anchorage Radiation Therapy Center — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska
  • Alaska Oncology and Hematology LLC — Anchorage, Alaska
  • Alaska Women's Cancer Care — Anchorage, Alaska
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Alaska:
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska
  • Alaska Oncology and Hematology LLC — Anchorage, Alaska
  • Alaska Women's Cancer Care — Anchorage, Alaska
  • Katmai Oncology Group — Anchorage, Alaska
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Alaska:
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Anchorage Radiation Therapy Center — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska
  • Alaska Oncology and Hematology LLC — Anchorage, Alaska
  • Alaska Women's Cancer Care — Anchorage, Alaska
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Alaska:
  • Alaska Womens Cancer Care Akwcc — Anchorage, Alaska
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed o…

Sponsor: AstraZeneca
NCT ID: NCT07816666
Sites in Alaska:
  • Research Site — Anchorage, Alaska
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Alaska:
  • Alaska Women's Cancer Care — Anchorage, Alaska
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Alaska:
  • Alaska Oncology and Hematology — Anchorage, Alaska
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves…

Sponsor: NRG Oncology
NCT ID: NCT04251052
Sites in Alaska:
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Anchorage Radiation Therapy Center — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska
  • Alaska Oncology and Hematology LLC — Anchorage, Alaska
  • Alaska Women's Cancer Care — Anchorage, Alaska
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19